unfortunately, low-density lipoprotein (ldl) and high-density lipoprotein (hdl) particle number and size, other lipoprotein subfractionation, apolipoproteins b and a, and lipoprotein(a) have not yet met current standards for biomarker evaluation, and it remains to be determined whether these tests incrementally add to cardiovascular risk predicted by traditional risk factors.